reports
- Michiel Declercq
Proximus Targeting € 400m FCF by 2030, dividend cut in FY26
Proximus reported solid 4Q25 results, with the underlying EBITDA of € 437m broadly in line with expectations (kbcse: € 433m, css: € 434m) while the FY25 organic FCF of € 130m came in slightly ahead (kbcse: € 107m, css: € 102m). Although the outlook 2026 was broadly in line, we welcome the lower capex spending of between € 1.20- € 1.25bn (kbcse: € 1.30bn, css: € 1.29bn), resulting in a better than expected FCF guidance for 2026 of up to € 100m (kbcse: € 39m, css: € 24m). By 2030, the group expect...
- Guy Sips
Materialise A Two-Speed Story
Materialise enters 2026 with diverging momentum across its business segments: - Medical continues to expand robustly, increasingly becoming the company's structural growth engine driven by deeper platform adoption and mass personalization. - Software is transitioning successfully toward a subscription-based, cloud-native AM workflow platform, with significant medium-term operating leverage. - Manufacturing faces persistent macro softness, particularly in European prototyping, with recovery depen...
- Livio Luyten
Texaf FY25 Results: Robust real estate drives +3% recurring operating ...
In FY25, TEXAF delivered solid results amid a complex DRC environment, marking its 100th anniversary with continued resilience. Real estate, the group's core driver, performed strongly with rental income up 13% to €30.8m. This was supported by full-year contributions from Promenade des Artistes and Silikin Village III, a near-100% residential occupancy, and 95% office occupancy. Like-for-like growth was 2.7%. The quarry segment struggled with a 17% revenue decline to €4.2m due to a 26% drop in ...
- Wim Hoste
Recticel FIRST LOOK: FY25 adj. EBITDA +12.5%; no guidance; CEO transit...
FY25 adjusted EBITDA increased by 12.5% and was in line with our forecasts while being 4% above consensus. Although expecting continued volume growth in 2026, Recticel does not provide a guidance at this stage, citing ao input cost volatility. CEO Jan Vergote will become Executive Chairman, while the current CEO of Recticel's Insulation Boards division, Stefaan Debusschere, will become new group CEO. Recticel still has significant firepower for additional acquisitions and we would expect the com...
- Mathijs Geerts Danau
mdxhealth FY25 revenues slightly below preliminary figures but guidanc...
mdxhealth's 4Q25 revenues come in $ 1m lower than the preliminary revenue figures shared in January ($ 30.5m). However the company maintains FY26 revenue guidance of $ 137-140m, implying 27-30% year-over-year revenue growth in FY26. Management also reiterated expectations for continued operating leverage, with a limited increase in OPEX despite significant revenue growth. As a result, mdxhealth expects to achieve a 10% adj. EBITDA run-rate by YE26. We reiterate our BUY and $ 6 TP.
- Mathijs Geerts Danau
Sequana Medical Reports 5 centres with alfapump implants since launch
Sequana announces progress in the commercial uptake of the alfapump. We estimate at least 8 implants across 5 hospitals since launch in 2H25. The soft-launch target was 70 implants by end of 1Q26. However, we view this target as challenging to reach. We therefore await FY25 results for greater visibility on definitive sales figures and launch metrics. We reiterate our BUY and € 2.7 TP.
- Kristof Samoy
Aalberts Good results & WC mgmt, higher DPS but lower SBB, no quantifi...
FY25 release was a mixed bag. Over FY25 Aalberts' topline came in above our expectations organically declining by only -2.5% vs. our -3.8% expectation. Topline stood at €3091m compared to our €3064mE and consensus of €3073mE. Adjusted EBITA of €410m was in line with our €405mE and CSS of €403mE. Overall EBITA margin was in line with earlier guidance at 13.3% (vs. 13.1% CSS, 13.2% KBC). The FCF & NWC management was solid. Declared DPS of €1.15 exceeded expectations but the announced SBB of €75m c...
- Wim Hoste
Corbion FIRST LOOK: FY25 EBITDA +27% organ., FY26 margin guidance of 1...
FY25 adj EBITDA increased by 27% organically and was close to our and consensus forecasts. FY26 guidance of a c. 100bps adj EBITDA margin improvement to around 17% is no surprise (KBCS 16.7%, CSS 16.9%). We remind that Corbion is conducting a strategic review on PLA which we believe will most likely result in an exit of Corbion, while still remaining the lactic acid supplier to the buyer. Biochemicals will be de-emphasized, which will put the growth focus on food preservation and formulation, al...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Wim Lewi
CTP FY25 in line, CTP start interest capitalisation in FY26
Gross Rental Income rose 14.4% YoY to €759.8m vs. €764.3m expected, supported by 4.5% like-for-like rental growth. EPRA EPS came in at €0.85, slightly below our €0.86 estimate due to some completions shifting into early 2026. Leasing remained robust, with new leases up 10% YoY. For FY26, CTP guides adj. EPRA EPS to € 1.01–1.03, of which €0.09 is related to the capitalisation of interest on debt for its development pipeline. The original range of €0.92-0.94 corresponds to our estimate of €0.91. L...
- Jacob Mekhael
argenx FY25 results come with positive phase 3 ocular MG readout
argenx reported $4.2b (CSS: $ 4.13b) in FY25 global product net sales and operating income of $ 1.1b marking 2025 argenx first year of operating profitability. A major update is the positive ocular MG readout that will expand the MG patient population with 7K patients. This year we look forward to the myositis readout in 3Q26 and the empasiprubart readout in MMN in 4Q26. We reiterate our € 900 TP and BUY rating.
- Wim Hoste
Bekaert FIRST LOOK: FY25 results in line with expectations, cautious g...
FY25 uEBIT was in line with earlier guidance and our and consensus forecasts. The FY26 guidance of a flat uEBIT margin is more cautious than our (+0.4pp) and consensus (+0.5pp) forecasts. The healthy free cash flow generation and solid balance sheet allow Bekaert to work on both M&A and share buybacks, and the current share buyback pace (c. €100m/y) in combination with the dividend imply a yearly attractive return to shareholders of c. 9%. With valuation still attractive, we maintain our BUY rat...
- Wim Lewi
Shurgard FY25 Results slightly ahead, growth returns in FY27
Shurgard FY25 EPRA net came ahead of our estimates at €173.1m versus €168.6m expected. The NTA per share rose an impressive 10% year-on-year to €53.30, driven by €519.5m fair-value gains in the portfolio. These gains are largely attributed to operational improvements rather than cap-rate compression. The FY25 same-store operating revenue grew 3.2%, a strong performance that indicates the organic growth remains on track. The EPRA EPS outlook for FY26 gives a range of €1.70 to €1.81 vs. €1.80 expe...
- Guy Sips
DEME Top-line in line, EBITDA-margin 22.4% vs our 20.8% (CSS 21.0%)
DEME posted a very solid FY25 with turnover of €4.2bn, broadly in line with expectations, supported by 4% y/y growth in Offshore Energy. Dredging & Infra maintained its record FY24 level at just under €2bn, while Environmental declined 19% y/y to €272m. The order book increased to €7.6bn, benefitting from new awards and the integration of Havfram. FY25 EBITDA rose 22% y/y to a very nice €9 30.5m (KBCSe €871.6m), lifting the margin to 22.4% on strong Offshore Energy performance. Dredging & In...
- Jacob Mekhael
UCB FY25 results show another Bimzelx-driven CSS beat
UCB reported another CSS beat with FY25 revenue of € 7,741m coming in 1.7% above expectations driven by stellar performance from Bimzelx, which generated € 2,227m in sales, 5.8% above expectations. We note that adj. EBITDA and net profit also came in above CSS despite increased investments in sales and marketing. With head to head data for Bimzelx vs. Skyrizi in PsA now expected in 1H26, we continue to view UCB as an attractive name to own, and reiterate our € 284 TP and BUY rating.
- Wim Hoste
Syensqo FIRST LOOK: Weak 4Q performance and disappointing FY26 outlook
4Q uEBITDA dropped by 20% and was 10% below our forecast and 11% below consensus. FY26 uEBITDA guidance of € 1.1bn represents a 7% drop y/y at similar scope and is c. 15% below our and consensus forecasts, due to a combination of elements (impact from a copper mine shutdown, weaker sales of a smart device customer, the phase out of some fluorosurfactants and a € 40m negative FX impact). We continue to believe valuation is attractive but will have to lower our forecasts significantly.
- Kristof Samoy
CMB.Tech Solid 4Q25 & 1Q26 fixtures, fleet renewal ongoing, LT contrac...
Over 4Q25, CMB.TECH reported a net profit of $90.1m ($0.31 p.s.). Corrected for $49.5m capital gains on vessel disposals the adjusted EBITDA was $272.5m well above our $215m forecast. A $0.16 p.s. interim dividend was declared. 1Q26 to date fixtures point to a strong start of the year and leave considerable upside to our assumptions. While the crude tanker rates are making headlines daily, we are impressed by the solid fixtures and rates in dry bulk, which makes up >50% of GAV. The contract back...
- Livio Luyten
GBL After delivering a solid recovery we expect momentum to moderate
GBL has reached our previous price target following its consistent performance since the Apr'25 Liberation Day low. Over this period, the discount compressed sharply from 45% to 22%, driven by visible strategy progress, growing recognition of unique private market access, and €335m share buybacks in FY25. The recent Rayner acquisition (€0.5bn for 45% co-control stake) marks the first clear execution of GBL's Nov'24 strategy to increase direct private asset exposure in priority sectors. It streng...
- Kristof Samoy
CFE FY25: In line results, solid debt reduction, margin strength in Co...
Over FY25, revenues equalled €1042m (-12% YoY) but EBIT up sharply at €44.9m (+40.3% YoY). The net result stood at €33.5m (LY: €24m). As such, the posted net result exceeds guidance calling for 2025 net profit close to the 2024 level. The company proposed a gross dividend of €0.50ps (€0.4PS LY). The consolidated order book stood at €1633m (vs. €1646m LY and €1650m per 9m25). Thanks to strong OCF of €64m, net debt turned into a net cash position of €43.8M (€41.7m net debt LY) . For 2026, CFE expe...
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.